BioXcel Non Current Liabilities Total from 2010 to 2024
| BTAI Stock | USD 0.41 0.04 8.89% |
Non Current Liabilities Total | First Reported 2019-03-31 | Previous Quarter 112.4 M | Current Value 109 M | Quarterly Volatility 51.1 M |
Check BioXcel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioXcel Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 14 M, Selling General Administrative of 66.7 M or Total Revenue of 1.4 M, as well as many indicators such as Price To Sales Ratio of 59.16, Dividend Yield of 0.0 or Days Sales Outstanding of 17.84. BioXcel financial statements analysis is a perfect complement when working with BioXcel Therapeutics Valuation or Volatility modules.
BioXcel | Non Current Liabilities Total |
Latest BioXcel Therapeutics' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of BioXcel Therapeutics over the last few years. It is BioXcel Therapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioXcel Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
BioXcel Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 20,716,343 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 204.38 | |
| Mean Deviation | 32,675,216 | |
| Median | 0.00 | |
| Standard Deviation | 42,340,512 | |
| Sample Variance | 1792.7T | |
| Range | 108.1M | |
| R-Value | 0.70 | |
| Mean Square Error | 974.2T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 6,663,789 | |
| Total Sum of Squares | 25098.1T |
BioXcel Non Current Liabilities Total History
About BioXcel Therapeutics Financial Statements
Investors use fundamental indicators, such as BioXcel Therapeutics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although BioXcel Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 102.9 M | 108.1 M |
Currently Active Assets on Macroaxis
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:Check out the analysis of BioXcel Therapeutics Correlation against competitors. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.